The use of a human papillomavirus 18 promoter for tissue-specific expression in cervical carcinoma cells

Cellular and Molecular Biology Letters

Volumn 16, Issue 3, 2011, Pages 477-492

  Lung, Mandy S Y ^a,b   Mak, Wendy M ^a,c   Murray, Vincent ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cervical cancer; E2 binding site; Gene therapy; HPV18; Long control region

Indexed keywords

DNA FRAGMENT; E2 PROTEIN; LUCIFERASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BINDING SITE; CARCINOMA CELL; CELL BASED GENE THERAPY; CELL LINE; CELL STRAIN C33A; CELL STRAIN H1299; CELL STRAIN MRC5; CELL STRAIN SIHA; CELL TYPE; CONTROLLED STUDY; FETUS; FIBROBLAST; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MUTATIONAL ANALYSIS; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS; TISSUE SPECIFICITY; UTERINE CERVIX CARCINOMA; VIRUS EXPRESSION;

HUMAN PAPILLOMAVIRUS - 18;

EID: 80052441278     PISSN: 14258153     EISSN: 16891392     Source Type: Journal    
DOI: 10.2478/s11658-011-0018-8     Document Type: Article

References (57)

1. Jo, H. and Kim, J. W. Implications of HPV infection in uterine cervical cancer. Cancer Ther. 3 (2005) 419-434.
2. Saslow, D., Castle, P. E., Cox, J. T., Davey, D. D., Einstein, M. H., Ferris, D. G., Goldie, S. J., Harper, D. M., Kinney, W., Moscicki, A. B., Noller, K. L., Wheeler, C. M., Ades, T., Andrews, K. S., Doroshenk, M. K., Kahn, K. G., Schmidt, C., Shafey, O., Smith, R. A., Partridge, E. E. and Garcia, F. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. C. A. Cancer J. Clin. 57 (2007) 7-28.
3. Morris, M., Eifel, P. J., Lu, J., Grigsby, P. W., Levenback, C., Stevens, R. E., Rotman, M., Gershenson, D. M. and Mutch, D. G. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 340 (1999) 1137-1143.
4. Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., Clarke-Pearson, D. L. and Insalaco, S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340 (1999) 1144-1153.
5. Thomas, G. M. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N. Engl. J. Med. 340 (1999) 1198-1200.
6. Rein, D. T. and Kurbacher, C. M. The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects. Anticancer Drugs12 (2001) 787-795.
7. Rein, D. T., Breidenbach, M., Wu, H., Han, T., Haviv, Y. S., Wang, M., Kirby, T. O., Kawakami, Y., Dall, P., Alvarez, R. D. and Curiel, D. T. Gene transfer to cervical cancer with fiber-modified adenoviruses. Int. J. Cancer111 (2004) 698-704.
8. Dorer, D. E. and Nettelbeck, D. M. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv. Drug. Deliv. Rev. 61 (2009) 554-571.
9. Chan, J. K. and Berek, J. S. Impact of the human papilloma vaccine on cervical cancer. J. Clin. Oncol. 25 (2007) 2975-2982.
10. Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond)110 (2006) 525-541.
11. Evans, M. F., Adamson, C. S., Schned, L. M., St John, T. L., Leiman, G., Ashikaga, T. and Cooper, K. HPV is detectable in virtually all abnormal cervical cytology samples after reinvestigation of HPV negatives with multiple alternative PCR tests. Diagn. Mol. Pathol. 19 (2010) 144-150.
12. Butz, K., Denk, C., Ullmann, A., Scheffner, M. and Hoppe-Seyler, F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6693-6697.
13. Steger, G., Rehtanz, M. and Schnabel, C. Identification of a promoter in position 56 within the long control region of human papillomavirus type 18. Arch. Virol. 146 (2001) 2069-2084.
14. Thierry, F., Heard, J. M., Dartmann, K. and Yaniv, M. Characterization of a transcriptional promoter of human papillomavirus 18 and modulation of its expression by simian virus 40 and adenovirus early antigens. J. Virol. 61 (1987) 134-142.
15. Yee, C., Krishnan-Hewlett, I., Baker, C. C., Schlegel, R. and Howley, P. M. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119 (1985) 361-366.
16. Romanczuk, H., Villa, L. L., Schlegel, R. and Howley, P. M. The viral transcriptional regulatory region upstream of the E6 and E7 genes is a major determinant of the differential immortalization activities of human papillomavirus types 16 and 18. J. Virol. 65 (1991) 2739-2744.
17. Bodily, J. and Laimins, L. A. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 19 (2011) 33-39.
18. Hansen, C. N., Nielsen, L. and Norrild, B. Activities of E7 promoters in the human papillomavirus type 16 genome during cell differentiation. Virus Res. 150 (2010) 34-42.
19. Moody, C. A. and Laimins, L. A. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer10 (2010) 550-560.
20. Hsu, K. F., Wu, C. L., Huang, S. C., Hsieh, J. L., Huang, Y. S., Chen, Y. F., Shen, M. R., Chung, W. J., Chou, C. Y. and Shiau, A. L. Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy. Cancer Gene Ther. 15 (2008) 526-534.
21. Sharma, R. and Palefsky, J. M. Addition of a single E2 binding site to the human papillomavirus (HPV) type 16 long control region enhances killing of HPV positive cells via HPV E2 protein-regulated herpes simplex virus type 1 thymidine kinase-mediated suicide gene therapy. Hum. Gene Ther. 21 (2010) 843-854.
22. von Knebel Doeberitz, M., Rittmuller, C., Zur Hausen, H. and Durst, M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int. J. Cancer51 (1992) 831-834.
23. Cole, S. T. and Danos, O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J. Mol. Biol. 193 (1987) 599-608.
24. Garcia-Carranca, A., Thierry, F. and Yaniv, M. Interplay of viral and cellular proteins along the long control region of human papillomavirus type 18. J. Virol. 62 (1988) 4321-4330.
25. Gius, D., Grossman, S., Bedell, M. A. and Laimins, L. A. Inducible and constitutive enhancer domains in the noncoding region of human papillomavirus type 18. J. Virol. 62 (1988) 665-672.
26. Bauknecht, T., Angel, P., Royer, H. D. and Zur Hausen, H. Identification of a negative regulatory domain in the human papillomavirus type 18 promoter: interaction with the transcriptional repressor YY1. EMBO J. 11 (1992) 4607-4617.
27. Hines, C. S., Meghoo, C., Shetty, S., Biburger, M., Brenowitz, M. and Hegde, R. S. DNA structure and flexibility in the sequence-specific binding of papillomavirus E2 proteins. J. Mol. Biol. 276 (1998) 809-818.
28. Swindle, C. S., Zou, N., van Tine, B. A., Shaw, G. M., Engler, J. A. and Chow, L. T. Human papillomavirus DNA replication compartments in a transient DNA replication system. J. Virol. 73 (1999) 1001-1009.
29. Tan, S. H., Gloss, B. and Bernard, H. U. During negative regulation of the human papillomavirus-16 E6 promoter, the viral E2 protein can displace Sp1 from a proximal promoter element. Nucleic Acids Res. 20 (1992) 251-256.
30. Thierry, F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology384 (2009) 375-379.
31. Sverdrup, F. and Khan, S. A. Two E2 binding sites alone are sufficient to function as the minimal origin of replication of human papillomavirus type 18 DNA. J. Virol. 69 (1995) 1319-1323.
32. Boner, W. and Morgan, I. M. Novel cellular interacting partners of the human papillomavirus 16 transcription/replication factor E2. Virus Res. 90 (2002) 113-118.
33. Demeret, C., Yaniv, M. and Thierry, F. The E2 transcriptional repressor can compensate for Sp1 activation of the human papillomavirus type 18 early promoter. J. Virol. 68 (1994) 7075-7082.
34. McBride, A. A., Romanczuk, H. and Howley, P. M. The papillomavirus E2 regulatory proteins. J. Biol. Chem. 266 (1991) 18411-18414.
35. McBride, A. and Myers, G. (1997) The E2 proteins. The E2 proteins. Los Alamos National Laboratory Bioscience Division.
36. McBride, A. A., Androphy, E. and Munger, K. (1998) Regulation of the papillomavirus E6 and E7 oncoprotreins by the viral E1 and E2 proteins, in: Regulation of the papillomavirus E6 and E7 oncoprotreins by the viral E1 and E2 proteins (Myers, G, Ed.) Addison-Wesley: p. 35-52.
37. Hoppe-Seyler, F. and Butz, K. Activation of human papillomavirus type 18 E6-E7 oncogene expression by transcription factor Sp1. Nucleic Acids Res. 20 (1992) 6701-6706.
38. Hoppe-Seyler, F., Butz, K. and Zur Hausen, H. Repression of the human papillomavirus type 18 enhancer by the cellular transcription factor Oct-1. J. Virol. 65 (1991) 5613-5618.
39. Bernard, B. A., Bailly, C., Lenoir, M. C., Darmon, M., Thierry, F. and Yaniv, M. The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes. J. Virol. 63 (1989) 4317-4324.
40. Finzer, P., Aguilar-Lemarroy, A. and Rosl, F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett. 188 (2002) 15-24.
41. Shillitoe, E. J. Papillomaviruses as targets for cancer gene therapy. Cancer Gene Ther. 13 (2006) 445-450.
42. Phelps, W. C. and Howley, P. M. Transcriptional trans-activation by the human papillomavirus type 16 E2 gene product. J. Virol. 61 (1987) 1630-1638.
43. Dostatni, N., Thierry, F. and Yaniv, M. A dimer of BPV-1 E2 containing a protease resistant core interacts with its DNA target. EMBO J. 7 (1988) 3807-3816.
44. Dong, G., Broker, T. R. and Chow, L. T. Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfering with the binding of host transcription factors to adjacent elements. J. Virol. 68 (1994) 1115-1127.
45. Dostatni, N., Lambert, P. F., Sousa, R., Ham, J., Howley, P. M. and Yaniv, M. The functional BPV-1 E2 trans-activating protein can act as a repressor by preventing formation of the initiation complex. Genes Dev. 5 (1991) 1657-1671.
46. Karstensen, B., Poppelreuther, S., Bonin, M., Walter, M., Iftner, T. and Stubenrauch, F. Gene expression profiles reveal an upregulation of E2F and downregulation of interferon targets by HPV18 but no changes between keratinocytes with integrated or episomal viral genomes. Virology353 (2006) 200-209.
47. 105 promoter by the coactivator CBP. Intervirology50 (2007) 418-425.
48. Ottinger, M., Smith, J. A., Schweiger, M. R., Robbins, D., Powell, M. L., You, J. and Howley, P. M. Cell-type specific transcriptional activities among different papillomavirus long control regions and their regulation by E2. Virology395 (2009) 161-171.
49. Teissier, S., Pang, C. L. and Thierry, F. The E2F5 repressor is an activator of E6/E7 transcription and of the S-phase entry in HPV18-associated cells. Oncogene29 (2010) 5061-5070.
50. 105 promoters. J. Virol. 64 (1990) 2849-2859.
51. Lace, M. J., Anson, J. R., Klingelhutz, A. J., Harada, H., Taniguchi, T., Bossler, A. D., Haugen, T. H. and Turek, L. P. Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1. Carcinogenesis30 (2009) 1336-1344.
52. Lace, M. J., Anson, J. R., Turek, L. P. and Haugen, T. H. Functional mapping of the human papillomavirus type 16 E1 cistron. J. Virol. 82 (2008) 10724-10734.
53. Lace, M. J., Isacson, C., Anson, J. R., Lorincz, A. T., Wilczynski, S. P., Haugen, T. H. and Turek, L. P. Upstream regulatory region alterations found in human papillomavirus type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture. J. Virol. 83 (2009) 7457-7466.
54. Lace, M. J., Anson, J. R., Haugen, T. H. and Turek, L. P. Interferon regulatory factor (IRF)-2 activates the HPV-16 E6-E7 promoter in keratinocytes. Virology399 (2010) 270-279.
55. Zarovni, N., Vago, R., Solda, T., Monaco, L. and Fabbrini, M. S. Saporin as a novel suicide gene in anticancer gene therapy. Cancer Gene Ther. 14 (2007) 165-173.
56. Shillitoe, E. J. and Noonan, S. Strength and specificity of different gene promoters in oral cancer cells. Oral Oncol. 36 (2000) 214-220.
57. Arendt, M. L., Nasir, L. and Morgan, I. M. A novel two-step transcriptional activation system for gene therapy directed toward epithelial cells. Mol. Cancer Ther. 8 (2009) 3244-3254.